Garner William
Gründer bei GENETETHER THERAPEUTICS INC.
Vermögen: 5 Mio $ am 30.04.2024
Aktive Positionen von Garner William
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GENETETHER THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 01.04.2018 | - |
Gründer | 12.02.2018 | - | |
GeneTether, Inc.
GeneTether, Inc. Miscellaneous Commercial ServicesCommercial Services GeneTether, Inc. develops gene editing technologies intended for human therapeutic applications. Its platform is focused on the treatment of rare, monogenic diseases of the kidney and the skin. The company was founded by William James Garner, R. Geoffrey Sargent, and Daren N. Graham on February 12, 2018 and is headquartered on California. | Direktor/Vorstandsmitglied | 12.02.2018 | - |
Gründer | 12.02.2018 | - | |
ISLA Pharamceuticals
ISLA Pharamceuticals Pharmaceuticals: MajorHealth Technology ISLA Pharmaceuticals develops therapies for tropical diseases. The private company is based in Puerto Rico. The American company was founded by William James Garner. | Direktor/Vorstandsmitglied | 01.01.2020 | - |
Gründer | 01.03.2017 | - | |
Vorsitzender | 01.03.2017 | 01.01.2020 | |
Innovation Angel Foundation, Inc. | Direktor/Vorstandsmitglied | - | - |
Update Pharma, Inc.
Update Pharma, Inc. Medical DistributorsDistribution Services Part of MDM Permian, Inc., Update Pharma, Inc. develops and provides anti-cancer drugs and other pharmaceutical products. The American company was founded by William James Garner. Update Pharma was acquired by BestnPet, Inc. on September 09, 2013. | Vorsitzender | - | - |
Gründer | - | - | |
EGB Ventures LLC
EGB Ventures LLC Investment ManagersFinance EGB Ventures LLC EGB Ventures) is a venture capital firm founded in 2010 by William (Bill) Garner. The firm is headquartered in Whitewright, Texas. | Chief Investment Officer | 05.01.2015 | - |
Gründer | 05.01.2015 | - | |
Private Equity Investor | 05.01.2015 | - |
Karriereverlauf von Garner William
Ehemalige bekannte Positionen von Garner William
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
INMED PHARMACEUTICALS INC. | Direktor/Vorstandsmitglied | 01.07.2016 | - |
Vorsitzender | 01.07.2016 | 15.12.2022 | |
Independent Dir/Board Member | 01.07.2016 | 15.12.2022 | |
TRYPTAMINE THERAPEUTICS LIMITED | Direktor/Vorstandsmitglied | 01.01.2020 | 18.02.2022 |
Vorsitzender | 24.09.2019 | 01.01.2020 | |
Gründer | 24.09.2019 | 18.02.2022 | |
RACE ONCOLOGY LIMITED | Direktor/Vorstandsmitglied | 06.03.2020 | 28.10.2020 |
Vorsitzender | 01.07.2016 | 06.03.2020 | |
Gründer | 01.07.2016 | 28.10.2020 | |
░░░ ░░░ ░░░░░░░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░ ░░░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░ ░░░░ ░░░░ | ░░░░░░░ | - | ░░░░░░░░░░ |
░░░░░░░░░ | - | ░░░░░░░░░░ | |
░░░░░░░░░ ░░░░ | ░░░░░░░░░ | - | ░░░░░░░░░░ |
░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░ | - | - |
Ausbildung von Garner William
New York Medical College | Doctorate Degree |
Harvard T.H. Chan School of Public Health | Graduate Degree |
Statistik
International
Vereinigte Staaten | 16 |
Kanada | 5 |
Australien | 3 |
Operativ
Founder | 14 |
Director/Board Member | 11 |
Chairman | 6 |
Sektoral
Health Technology | 15 |
Consumer Services | 3 |
Distribution Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 6 |
---|---|
INVION LIMITED | Health Technology |
KINTARA THERAPEUTICS, INC. | Health Technology |
RACE ONCOLOGY LIMITED | Health Technology |
INMED PHARMACEUTICALS INC. | Health Technology |
ROCHE HOLDING AG | Health Technology |
GENETETHER THERAPEUTICS INC. | Health Technology |
Private Unternehmen | 14 |
---|---|
Urigen N.A, Inc. | Health Technology |
Del Mar Pharmaceuticals (BC) Ltd.
Del Mar Pharmaceuticals (BC) Ltd. Pharmaceuticals: MajorHealth Technology Part of Kintara Therapeutics, Inc., Del Mar Pharmaceuticals (BC) Ltd. provides drug development services. The private company is based in Vancouver, Canada. The Canadian company was founded by William James Garner, Jeffrey A. Bacha, Dennis M. Brown. Jeffrey A. Bacha has been the CEO since incorporation. Del Mar Pharmaceuticals (BC was acquired by Kintara Therapeutics, Inc. on January 25, 2013 for $0.65 million. | Health Technology |
Igxbio, Inc.
Igxbio, Inc. Pharmaceuticals: MajorHealth Technology Igxbio, Inc. develops DNA immunotherapies for HIV infection. It offers GenePro, a DNA therapeutic incorporating a DNA composition that yields high levels of gene expression and non-infectious HIV protein production, and induces an antibody and cellular immune response in animal models, including non-human primates. The company was founded in 2002 and is headquartered in Fairway, KS. | Health Technology |
Paramount Capital, Inc. | |
Roche Laboratories, Inc.
Roche Laboratories, Inc. Medical DistributorsDistribution Services Part of Roche Holding AG, Roche Laboratories, Inc. markets and sells pharmaceutical medications. The private company is based in Nutley, NJ. | Distribution Services |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | Health Technology |
EGB Ventures LLC
EGB Ventures LLC Investment ManagersFinance EGB Ventures LLC EGB Ventures) is a venture capital firm founded in 2010 by William (Bill) Garner. The firm is headquartered in Whitewright, Texas. | Finance |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | Health Technology |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
Update Pharma, Inc.
Update Pharma, Inc. Medical DistributorsDistribution Services Part of MDM Permian, Inc., Update Pharma, Inc. develops and provides anti-cancer drugs and other pharmaceutical products. The American company was founded by William James Garner. Update Pharma was acquired by BestnPet, Inc. on September 09, 2013. | Distribution Services |
Innovation Angel Foundation, Inc. | |
ISLA Pharamceuticals
ISLA Pharamceuticals Pharmaceuticals: MajorHealth Technology ISLA Pharmaceuticals develops therapies for tropical diseases. The private company is based in Puerto Rico. The American company was founded by William James Garner. | Health Technology |
Tryp Therapeutics, Inc.
Tryp Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tryp Therapeutics, Inc. is a pharmaceutical company, which engages in identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. The company was founded on September 24, 2019 and is headquartered in Kelowna, Canada. | Health Technology |
GeneTether, Inc.
GeneTether, Inc. Miscellaneous Commercial ServicesCommercial Services GeneTether, Inc. develops gene editing technologies intended for human therapeutic applications. Its platform is focused on the treatment of rare, monogenic diseases of the kidney and the skin. The company was founded by William James Garner, R. Geoffrey Sargent, and Daren N. Graham on February 12, 2018 and is headquartered on California. | Commercial Services |
- Börse
- Insiders
- Garner William
- Erfahrung